Very pertinent especially for early stage breast cancer on curative-intent therapy. Great to have definitive data 📈 we can use in counseling patients SABCS #sabcs24

This is promising! I’m keen on an abema-based combination/doublet regimen that’s 💯 orally administered SABCS #sabcs24

This was an interesting paper. Equally interesting was the question of, “How much chemo is too little?” pCR is a surrogate for overall outcomes but without ctDNA or other microscopic level evaluation, can we ever be confident re: longterm outcomes? SABCS #sabcs24

This was great to see! I agree that we should probably extrapolate to PALB2 mutated. How to sequence olaparib with adj pembro +/- xeloda? SABCS #sabcs24

“ADCs are not available everywhere”…..a reminder at #sabcs24 Case Discussions. #healthdisparities #GlobalHealth SABCS

INSEMA: SLNB vs no SLNB iDFS events 91.7% vs 91.9% , n=4858 5 yr OS :96.9 vs 98.2% Omitting SLNB in pts with early breast cancer and cN0 and s/f breast-conserving tx did not result in inferior outcome Now in NEJM SABCS #SABCS24 OncoAlert

It's a difficult topic to discuss- weight. Hugely personal, not easy to change, but impt. 4% ⬆️ recurrence in pts w/ node + #bcsm obese vs. lean 2% ⬆️ recurrence in pts with N0 dz 📌Magnitude of effect larger among premeno. 📌ER + AND ER neg SABCS #SABCS24

I’m a bit uncertain here with OS immature at 78 month f/u Are we going to have a replay of the PALOMA story? SABCS #sabcs24

Takeaways from ZEST 📌short lead time between det of ctDNA and recurrence ~5mos 📌Pts who had ➖ ctDNA conv to➕within 3mos with MBC on imaging. 📌 pts with ctDNA have💯recurrence 📌 no data yet that intervening on ➕ctDNA improves outcome. OncoAlert #SABCS24

At #SABCS24 GS3 Impact of Anthracyclines in High Genomic Risk Node-Negative HR+/HER2- Breast Cance - a post-hoc analysis of TAILOR-X Significant benefit in DRFI and DRFS with anthracyclines in this population OncoAlert

I’ve typically recommended AC-T for the super-high Oncotype RS cases. It’s great to see data supporting this practice. Well done to the UChicago Medicine team SABCS #SABCS24

GeaprDouze (NSABP B-59) preop chemo+/- atezo in early TNBC 4 yr EFS 81.9% vs 85.2%, HR 0.80, p=0.08 OS HR 0.86 Nodal Status: N+: HR: 0.62, n-: HR 1.0 pCR: 57% vs 63.3% Atezo did not add significant benefit in EFS SABCS #SABCS24 OncoAlert #bcsm

📌 Multimodal Integration of Real World Clinical and Genomic Data for the Prediction of CDK4/6 Inhibitors Outcomes in Patients with HR+/HER2- Metastatic Breast Cancer by Pedram Razavi 👏🏻 #SABCS24 #day4 OncoAlert #OncoAlertAF

This was an excellent summary by Dr Tsang SABCS #SABCS24 👏🏾👏🏾👏🏾

Excellent summary by Dr Danso 👏🏾👏🏾👏🏾 SABCS #SABCS24

Treatment algorithm for HR pos HER2 neg MBC in 2024, including HER2 low and ultra low, by Dr Danso SABCS #SABCS24

Treatment algorithm for HER2 pos MBC in 2024 from Dr Danso SABCS #SABCS24

I totally agree. It’s also time to move on from purely adj IO (without neoadj) IO. We should channel efforts towards identification of predictive biomarkers SABCS #SABCS24

Hmm…. Patients still asking for MRD assays….what to do?

MBC HR POs treatment algorithm SABCS #SABCS24